SAN DIEGO, Sept. 13, 2021 /PRNewswire/ -- Inhibrx, Inc.
(NASDAQ: INBX), a clinical-stage biotechnology company focused on
developing a broad pipeline of novel biologic therapeutic
candidates, announced today that the Company will be presenting at
the following upcoming virtual investor conference:
- 2021 Cantor Virtual Global Healthcare Conference; Wednesday, September 29th, at 8:40 a.m. Pacific Time
The investor conference presentation will be webcast live and
may be accessed through a link on the investors section of
Inhibrx's website at
https://inhibrx.investorroom.com/events-and-presentations. The
webcast will be available for 60 days following the event.
About Inhibrx, Inc.
Inhibrx is a clinical-stage biotechnology company focused on
developing a broad pipeline of novel biologic therapeutic
candidates in oncology and orphan diseases. Inhibrx utilizes
diverse methods of protein engineering to address the specific
requirements of complex target and disease biology, including its
proprietary sdAb platform. Inhibrx has collaborations with bluebird
bio, Bristol-Myers Squibb and Chiesi. For more information, please
visit www.inhibrx.com.
Investor and Media Contact:
Kelly Deck
CFO
kelly@inhibrx.com
858-795-4260
View original content to download
multimedia:https://www.prnewswire.com/news-releases/inhibrx-announces-participation-in-upcoming-investor-conference-301375171.html
SOURCE Inhibrx, Inc.